MIGUEL ALBINO MD NPI 1205060746

NPI Information

  • NPI: 1205060746
  • Provider Name: MIGUEL ALBINO, MD
  • Classification: Internal Medicine - 207RX0202X
  • Specialization: Medical Oncology
  • Entity Type: Individual
  • PECOS Registration: Yes
  • Address: 12221 RENFERT WAY STE 300
    AUSTIN, TX
    ZIP 78758
  • Phone: (512) 873-8900

Map and Directions

Get Directions

NPI Details

Miguel Albino, MD is a medical oncology internal medicine in Austin, TX with 17 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. Miguel Albino, MD NPI is 1205060746. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

12221 RENFERT WAY STE 300
AUSTIN, TX
ZIP 78758-453
Phone: (512) 873-8900
Fax: (512) 873-8913

The NPI 1205060746 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

  • Injection, iron sucrose, 1 mg (HCPCS:J1756)
  • Injection, fosaprepitant, 1 mg (HCPCS:J1453)
  • Injection, paclitaxel, 1 mg (HCPCS:J9267)
  • Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
  • Injection, pembrolizumab, 1 mg (HCPCS:J9271)
  • Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
  • Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
  • Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
  • Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
  • Injection of additional new drug or substance into vein (HCPCS:96375)
  • Injection, carboplatin, 50 mg (HCPCS:J9045)
  • Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
  • Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
  • Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
  • Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
  • Insertion of needle into vein for collection of blood sample (HCPCS:36415)
  • Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
  • Blood test, comprehensive group of blood chemicals (HCPCS:80053)
  • Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
  • Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
  • Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
  • Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
  • Infusion into a vein for hydration, each additional hour (HCPCS:96361)
  • Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
  • Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
  • Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
  • Injection of drug or substance under skin or into muscle (HCPCS:96372)
  • Injection, zoledronic acid, 1 mg (HCPCS:J3489)
  • Gammaglobulin (immune system protein) measurement (HCPCS:82784)
  • Unclassified drugs (HCPCS:J3490)
  • Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
  • Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
  • Irrigation of implanted venous access drug delivery device (HCPCS:96523)
  • Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
  • Measurement of immunoglobulin light chains (HCPCS:83521)
  • Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
  • Lactate dehydrogenase (enzyme) level (HCPCS:83615)
  • Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
  • Ferritin (blood protein) level (HCPCS:82728)
  • Reticulated (young) platelet measurement (HCPCS:85055)
  • Iron level (HCPCS:83540)
  • Iron binding capacity (HCPCS:83550)
  • New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
  • Complete blood cell count (red cells, white blood cell, platelets), automated test (HCPCS:85027)
  • Microscopic examination for white blood cells with manual cell count (HCPCS:85007)
  • Protein measurement, serum (HCPCS:84165)
  • Immunologic analysis technique on serum (HCPCS:86320)
  • Immunologic analysis technique on serum (immunofixation) (HCPCS:86334)
  • Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
  • Red blood count, automated test (HCPCS:85045)
  • Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
  • Drawing of blood for a medical problem (HCPCS:99195)
  • Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
  • Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
  • Beta-2 microglobulin (protein) level (HCPCS:82232)
  • Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
  • Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session (HCPCS:G6015)
  • Administration of influenza virus vaccine (HCPCS:G0008)
  • Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
  • Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage (HCPCS:90694)

The enumeration date for this NPI number is 5/13/2009 and was last updated on 11/13/2024.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

No. Taxonomy Code Taxonomy Clasification Taxonomy Specialization License Number License State Primary
1207RX0202XInternal MedicineMedical OncologyQ7825TEXASYes
2207R00000XInternal Medicine18296PUERTO RICONo

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.

No. Other Provider Identifier Other Provider Identifier Type Other Provider Identifier State Other Provider Identifier Issuer
1P01752684OTHERTEXASRAILROAD
2357925202MEDICAIDTEXAS
3357925201MEDICAIDTEXAS

What is NPI?

NPI stands for National Provider Identifier. The NPI is a 10-digit identification number that is completely unique. The NPI number by itself does not contain any identifiable information such as a provider’s speciality or location. The NPI is assigned to individuals or organizacions for their lifespan and it is independent of key provider information type updates like a change of practices, location or speciality.

This page was last updated on: 11/21/2025

NPI Synchronization or Removal

All materials and services on this site are provided on an "as is" and "as available" basis without warranty of any kind. The NPI record is maintained by the National Plan & Provider Enumeration System (NPPES) and anyone may request this information and other NPPES health care provider data from HHS under The Freedom of Information Act (FOIA), Title 5 of the United States Code, section 552. To update the NPI records please contact the NPPES.